Open-label riluzole in fragile X syndrome

• Published in: Brain research Vol. 1380; pp. 264 - 270
• Main Authors: Erickson, Craig A., Weng, Ning, Weiler, Ivan Jeanne, Greenough, William T., Stigler, Kimberly A., Wink, Logan K., McDougle, Christopher J.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 22.03.2011
• Subjects: administration & dosage; adults; adverse effects; animal models; biomarkers; brain; Child; Child Development Disorders, Pervasive; Child Development Disorders, Pervasive - drug therapy; Child Development Disorders, Pervasive - physiopathology; Child Development Disorders, Pervasive - psychology; children; drug therapy; drugs; ERK; Excitatory Amino Acid Antagonists; Excitatory Amino Acid Antagonists - administration & dosage; Excitatory Amino Acid Antagonists - adverse effects; Fragile X Syndrome; Fragile X Syndrome - drug therapy; Fragile X Syndrome - metabolism; Fragile X Syndrome - physiopathology; glutamic acid; Humans; liver function; Male; metabolism; Neurology; Neuroprotective Agents; Neuroprotective Agents - administration & dosage; Neuroprotective Agents - adverse effects; pathophysiology; people; physiopathology; Pilot Projects; Prospective Studies; psychology; Riluzole; Riluzole - administration & dosage; Riluzole - adverse effects; Young Adult; Riluzole; Fragile X syndrome; ERK

Objective. Glutamatergic dysregulation is implicated in the pathophysiology of fragile X syndrome (FXS). Riluzole is hypothesized to have an inhibitory effect on glutamate release, block excitotoxic effects of glutamate, and potentiate postsynaptic GABA(A) receptor function. Extracellular signal-rel...